pET28 E2 LBD-Tev-E1a-His
(Plasmid
#232117)
-
PurposeFor bacterial expression of a fusion protein containing from N to C-terminus: the lipoyl-binding domain of Human E2, a TEV protease site, a peptide from Human E1a, and a His tag.
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 232117 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepet28
- Backbone size w/o insert (bp) 5239
- Total vector size (bp) 5635
-
Vector typeBacterial Expression
Growth in Bacteria
-
Bacterial Resistance(s)Kanamycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberLow Copy
Gene/Insert
-
Gene/Insert nameDBT
-
Alt nameBCKDHE2
-
Alt nameLipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex
-
SpeciesH. sapiens (human)
-
Insert Size (bp)403
-
Entrez GeneDBT (a.k.a. BCATE2, BCKAD-E2, BCKADE2, BCKDH-E2, BCOADC-E2, E2, E2B)
- Promoter T7 Promoter
-
Tags
/ Fusion Proteins
- RIGHHSTSDDSSAY (AA331 to 345 (preprocessing, NP_000700.1) of E1a BCKD complex subunit) (C terminal on insert)
- 6xHis (C terminal on insert)
- Tev Protease Site (C terminal on insert)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site NcoI (not destroyed)
- 3′ cloning site NotI (not destroyed)
- 5′ sequencing primer T7 Forward
- 3′ sequencing primer T7 Reverse (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pET28 E2 LBD-Tev-E1a-His was a gift from Ruth Sommese (Addgene plasmid # 232117 ; http://n2t.net/addgene:232117 ; RRID:Addgene_232117) -
For your References section:
Structural studies identify angiotensin II receptor blocker-like compounds as branched-chain ketoacid dehydrogenase kinase inhibitors. Liu S, Kormos BL, Knafels JD, Sahasrabudhe PV, Rosado A, Sommese RF, Reyes AR, Ward J, Roth Flach RJ, Wang X, Buzon LM, Reese MR, Bhattacharya SK, Omoto K, Filipski KJ. J Biol Chem. 2023 Mar;299(3):102959. doi: 10.1016/j.jbc.2023.102959. Epub 2023 Jan 28. 10.1016/j.jbc.2023.102959 PubMed 36717078